What is the recommended treatment for a typical adult with confirmed COVID‑19?

Treatment for COVID-19

For typical adults with confirmed COVID-19, treatment depends critically on disease severity and risk factors: outpatients at high risk for progression should receive nirmatrelvir-ritonavir (first-line) or molnupiravir within 5 days of symptom onset, while hospitalized patients with severe disease require dexamethasone and prophylactic anticoagulation, with oxygen support escalated as needed.

Outpatient Management (Mild to Moderate Disease)

Risk Stratification First

Identify patients at high risk for progression to severe disease:

• Age >65 years
• Immunocompromised status
• Multiple comorbidities (diabetes, cardiovascular disease, chronic lung disease, obesity)
• Unvaccinated or inadequately vaccinated status

Antiviral Treatment (Within 5 Days of Symptom Onset)

First-line: Nirmatrelvir-ritonavir 1, 2

• Consider this for all high-risk patients with mild-moderate COVID-19
• Most effective antiviral option with greatest reduction in hospitalization
• Major caveat: Extensive drug-drug interactions due to ritonavir component—review all medications carefully

Second-line: Molnupiravir 3, 1, 2

• Use when nirmatrelvir-ritonavir is contraindicated or unavailable
• Moderate certainty evidence for reducing hospitalization and mortality
• Important safety concerns: Potential long-term risks including theoretical carcinogenicity based on preclinical data and mutagenic mechanism of action
• Should not be used in children due to effects on bone growth in animal studies

Third-line: Remdesivir (3-day course) 2

• Consider for high-risk patients within 7 days of symptom onset when oral antivirals unsuitable
• Requires IV administration, limiting outpatient feasibility

What NOT to Use in Outpatients

Do not prescribe the following—they lack efficacy or are ineffective against current variants 1, 2:

• Ivermectin
• Hydroxychloroquine
• Azithromycin (unless bacterial coinfection confirmed)
• Sotrovimab (ineffective against current Omicron variants)
• Convalescent plasma
• Corticosteroids (no role in mild-moderate outpatient disease)

Hospitalized Patients (Severe Disease)

Defining Severe Disease

• Respiratory rate >30 breaths/minute
• Oxygen saturation <94% on room air
• Respiratory distress
• Need for supplemental oxygen 4, 5

Core Treatment Components

1. Oxygen Therapy 6, 5

• Start at 5 L/min, titrate to SpO2 ≥94%
• Escalation pathway:
  • Nasal cannula/mask oxygen
  • High-flow nasal oxygen (HFNO)
  • Non-invasive ventilation (NIV)
  • Invasive mechanical ventilation if severe hypoxemia persists
  • ECMO for refractory hypoxemia

2. Dexamethasone 7, 5

• Strong evidence for mortality reduction in severe/critical COVID-19
• Dose: 6 mg daily for 10 days (or methylprednisolone 0.5-1 mg/kg/day for 3-7 days)
• Only use in patients requiring oxygen—harmful in mild disease
• Do not use if active bacterial/fungal infection suspected

3. Prophylactic Anticoagulation 8, 5

• All hospitalized patients should receive prophylactic-dose LMWH unless contraindicated
• COVID-19 creates prothrombotic state through inflammation, endothelial injury, and hypercoagulability
• Consider intensified prophylaxis if additional risk factors present (obesity, elevated D-dimers, ICU admission)

4. Remdesivir 4, 7

• Weak recommendation for hospitalized patients
• May improve time to clinical improvement (moderate certainty)
• Uncertain mortality benefit
• Monitor for hepatotoxicity, renal dysfunction, hyperglycemia

5. Tocilizumab (IL-6 inhibitor) 7

• Consider for severe COVID-19 with evidence of hyperinflammation
• Use in conjunction with corticosteroids, not as monotherapy
• Check inflammatory markers (CRP, ferritin) and ensure no active infections

Special Populations in Hospital

Patients with Pre-existing Antiplatelet/Anticoagulation Therapy 8

• Continue existing antiplatelet therapy for prior ACS or stroke
• Add prophylactic-dose LMWH in non-ICU patients
• For ICU patients on antiplatelet therapy: continue antiplatelet + prophylactic LMWH
• Individualize decisions when combining therapeutic anticoagulation with antiplatelet therapy—assess bleeding risk carefully

New-onset Atrial Fibrillation 8

• Hospitalized patients: Start therapeutic-dose parenteral anticoagulation immediately regardless of CHA2DS2-VASc score
• Transition to oral anticoagulation (DOAC preferred) if CHA2DS2-VASc ≥1 (men) or ≥2 (women)

Critical Illness (ICU Patients)

Escalate to ICU if 6:

• SpO2 <90% despite oxygen
• Severe dyspnea
• High respiratory rate despite intervention
• Hemodynamic instability

Additional ICU Considerations:

• Continue dexamethasone
• Prophylactic LMWH (continue even with antiplatelet therapy)
• Consider additional immunomodulation (tocilizumab, baricitinib) if worsening inflammation despite steroids 9
• Vilobelimab (anti-C5a antibody) may be considered within 48 hours of mechanical ventilation 10

Monitoring Requirements

All hospitalized patients 6:

• Vital signs: heart rate, oxygen saturation, respiratory rate, blood pressure
• Laboratory: CBC, CRP, PCT, liver enzymes, renal function, coagulation studies, D-dimer
• Arterial blood gas if severe hypoxemia
• Serial chest imaging as clinically indicated

Key Pitfalls to Avoid

1. Do not delay antiviral treatment in high-risk outpatients—efficacy drops significantly after 5 days
2. Do not use corticosteroids in mild-moderate outpatient disease—no benefit and potential harm
3. Do not withhold prophylactic anticoagulation in hospitalized patients without clear contraindication
4. Do not prescribe antibiotics empirically unless bacterial coinfection is suspected or confirmed 6, 7
5. Check drug interactions before prescribing nirmatrelvir-ritonavir—ritonavir is a potent CYP3A4 inhibitor

Evidence Quality Note

The 2023 American College of Chest Physicians guidelines 8 and 2025 ECIL-10 guidelines 9 represent the most recent high-quality guidance, though they focus primarily on specific complications (thrombosis) and special populations (hematologic malignancies). The 2026 American College of Physicians practice points 1 provide the most current outpatient antiviral recommendations. Most recommendations remain conditional due to evolving evidence and variant changes, but the core principles—early antivirals for high-risk outpatients, dexamethasone plus anticoagulation for hospitalized patients—have strong consensus support.